Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Growth in Short Interest

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 14,100 shares, an increase of 12.8% from the August 15th total of 12,500 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 6,000 shares, the short-interest ratio is currently 2.4 days.

Anebulo Pharmaceuticals Stock Performance

NASDAQ:ANEB traded down $0.01 during mid-day trading on Monday, hitting $2.08. 2,300 shares of the company’s stock traded hands, compared to its average volume of 5,792. The company has a market cap of $53.94 million, a PE ratio of -5.62 and a beta of -1.01. The firm’s 50 day simple moving average is $2.09 and its 200 day simple moving average is $2.39. Anebulo Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $3.71.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.